LogicBio Therapeutics Shares Outstanding 2018-2021 | LOGC

LogicBio Therapeutics shares outstanding from 2018 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
LogicBio Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 25
2019 23
2018 6
2017 1
LogicBio Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 32
2021-03-31 32
2020-12-31 25
2020-09-30 24
2020-06-30 23
2020-03-31 23
2019-12-31 23
2019-09-30 23
2019-06-30 22
2019-03-31 22
2018-12-31 6
2018-09-30 2
2018-06-30 2
2018-03-31 2
2017-12-31
2017-09-30 1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.146B $0.003B
LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company's technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71